cytarabine has been researched along with Triple Negative Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aittomäki, K; Blomqvist, C; Carpén, O; Fagerholm, R; Heikkilä, P; Heikkinen, T; Khan, S; Korpela, T; Nevanlinna, H | 1 |
1 other study(ies) available for cytarabine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Eukaryotic Initiation Factor-4E; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Paraffin Embedding; Phenotype; Prognosis; Protein Biosynthesis; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |